Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma
ChiCTR2600123643Phase 4Not yet recruiting
- Sponsor
- Yancheng First People's Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Yancheng First People's Hospital. Primary endpoint: Objective Response Rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600123643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123643.